Logan Zemp

643 total citations
45 papers, 327 citations indexed

About

Logan Zemp is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Logan Zemp has authored 45 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Surgery, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Logan Zemp's work include Bladder and Urothelial Cancer Treatments (20 papers), Renal cell carcinoma treatment (12 papers) and Urinary and Genital Oncology Studies (11 papers). Logan Zemp is often cited by papers focused on Bladder and Urothelial Cancer Treatments (20 papers), Renal cell carcinoma treatment (12 papers) and Urinary and Genital Oncology Studies (11 papers). Logan Zemp collaborates with scholars based in United States, Canada and Ireland. Logan Zemp's co-authors include Steven M. Ornstein, Wade J. Sexton, Keith Rourke, Philippe E. Spiess, Scott M. Gilbert, Ali Hajiran, Roger Li, Ruth Jenkins, Jasreman Dhillon and Rohit Jain and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Logan Zemp

35 papers receiving 320 citations

Peers

Countries citing papers authored by Logan Zemp

Since Specialization

Citations

This map shows the geographic impact of Logan Zemp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Logan Zemp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Logan Zemp more than expected).

Fields of papers citing papers by Logan Zemp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Logan Zemp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Logan Zemp. The network helps show where Logan Zemp may publish in the future.

Co-authorship network of co-authors of Logan Zemp

This figure shows the co-authorship network connecting the top 25 collaborators of Logan Zemp. A scholar is included among the top collaborators of Logan Zemp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Logan Zemp. Logan Zemp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	NATURAL HISTORY AND MANAGEMENT OF PENILE CANCER PATIENTS AFTER ORGAN-SPARING SURGERY WITH PEIN POSITIVE MARGINS	Urologic Oncology Seminars and Original Investigations	Logan Zemp, Peter A.S. Johnstone et al.	0
2	Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions.	Journal of Clinical Oncology	Jad Chahoud, Marine Potez et al.	0
3	Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma	Scientific Reports	Xiaoqing Yu, Taylor Peak et al.	3
4	OUTCOMES OF PATIENTS TREATED WITH ADDITIONAL BCG FOLLOWING A BCG UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER DIAGNOSIS	Urologic Oncology Seminars and Original Investigations	Justin Miller, Hongzhi Xu et al.	1
5	Management of Bulky Inguinal and Pelvic Lymph Nodes	Urologic Clinics of North America	Logan Zemp, Curtis A. Pettaway et al.	1
6	Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).	Journal of Clinical Oncology	Billie Gould, Prithvi Murthy et al.	0
7	Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).	Journal of Clinical Oncology	Roger Li, Philippe E. Spiess et al.	1
8	Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer	Urologic Oncology Seminars and Original Investigations	Roger Li, Wenyi Fan et al.	1
9	Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients	Urology	José A. Karam, Viraj A. Master et al.	2
10	The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features	European Urology Oncology	E. Jason Abel, Viraj A. Master et al.	16
11	Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals	European Urology Open Science	Daniel D. Shapiro, José A. Karam et al.	18
12	Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?	Frontiers in Oncology	Jacob J. Adashek, Yumeng Zhang et al.	6
13	Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder	Urologic Oncology Seminars and Original Investigations	Nicholas H. Chakiryan, Da Jiang et al.	1
14	Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy	Urologic Oncology Seminars and Original Investigations	Ahmet Murat Aydın, Richard R. Reich et al.	1
15	Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma	PLoS ONE	Nicholas H. Chakiryan, Youngchul Kim et al.	15
16	Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma	Urologic Oncology Seminars and Original Investigations	Ali Hajiran, Logan Zemp et al.	0
17	Improved artificial urinary sphincter outcomes using a transcorporal cuff placement in patients with a “fragile urethra”	Canadian Urological Association Journal	Keith Rourke, Steven Y. C. Tong et al.	14
18	Contemporary management of early stage testicular seminoma	Translational Andrology and Urology	Ahmet Murat Aydın, Logan Zemp et al.	8
19	Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity	Urologic Oncology Seminars and Original Investigations	Ali Hajiran, Logan Zemp et al.	2
20	Contemporary management of renal trauma in Canada: A 10-year experience at a level 1 trauma centre	Canadian Urological Association Journal	Logan Zemp, Keith Rourke et al.	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact